anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a swine foot-and-mouth disease virus O-type Fc polypeptide vaccine, a preparation method and application thereof. The O-type Fc polypeptide vaccine of the swine foot-and-mouth disease virus contains a soluble O-type Fc polypeptide of the swine foot-and-mouth disease virus, which is obtained by expressing a nucleotide sequence shown in SEQ ID NO.1 by a prokaryotic expression system. The invention optimizes the codon of the nucleotide sequence of the disclosed O-type broad-spectrum multi-epitope recombinant antigen for coding the foot-and-mouth disease virus, and then realizes the soluble expression and purification of the target protein by reconstructing recombinant plasmids and optimizing induction and culture conditions. The soluble protein simulates the characteristics of natural antigen to the maximum extent, and has stronger immunogenicity and higher antibody level. In addition, the vaccine prepared by the invention is simpler in components, does not contain 3D protein components, reduces the total protein content of the vaccine, improves the immune efficacy and reduces the vaccine cost. The invention provides material storage and technical support for prevention and control of the O-type foot-and-mouth disease of the pigs in China, and has important significance.
The invention discloses an anti-osteoporosis Chinese medicinal preparation, which is prepared from the following bulk pharmaceuticals in parts by weight: 4-6 parts of epimedium herb, 4-6 parts of kudzuvine root, 4-6 parts of himalayan teasel root, 1-3 parts of deer horn gelatin and 0.1-0.2 part of oyster. The invention further discloses a preparation method of the anti-osteoporosis Chinese medicinal preparation. The method is easy to operate and implement. A formula for treating post-menopause osteoporosis is obtained according to the conventional kidney-invigorating and bone-supporting theory and the modern plant isoflavone theory. Treatment of osteoporosis with the formula is not reported relatively in the prior art. Each medicinal ingredient in the formula acts in a coordinated way and has the effects of nourishing liver and kidney and strengthening the bones and muscles, and plant isoflavone is used for replacing in-vivo insufficient female hormones, so that double effects are achieved, and good prevention and control effects on post-menopause osteoporosis are achieved.
XHANCE (fluticasone propionate) nasal spray is supplied as a non-removable amber glass bottle fitted with a metered-dose manual spray pump unit inside the white XHANCE device with a nasal applicator, valve mechanism, asymmetrical cone-shaped nosepiece, flexible mouthpiece, base, and orange cap in a box of 1 (NDC 71143-375-01) with FDA‑approved Patient Labeling [see Instructions for Use].

Each bottle contains a net fill content of 16 mL, and after priming will provide 120 metered sprays. Each metered spray delivers 93 mcg of fluticasone propionate in an aqueous suspension through the cone‑shaped nosepiece. The correct amount of medication in each metered spray cannot be assured after 120 metered sprays even though the bottle is not completely empty. The bottle should be discarded when the labeled number of metered sprays has been used.

Store at room temperature (between 15°C and 25°C; 59°F and 77°F), excursions permitted from 15°C to 30°C (59°F to 86°F). Avoid exposure to extreme heat, cold or light. Shake XHANCE before each use.
PURPOSE: A nucleic acid molecule encoding a polypeptide which is able to bind to two different growth factors is provided to suppress or reduce plasma leakage and block angiogenesis. CONSTITUTION: A nucleic acid encodes a polypeptide containing two components which bind to two different cytokines. The nucleic acid molecule encodes a polypeptide which binds to the VEGF polypeptide and angiopoietin polypeptide. The polypeptide contains Tie2 component and VEGFR component. The components operably linked to a nucleotide sequence encoding multimerizing component. The Tie2 component necessarily comprises Ig-like domain 1, Ig-like domain 2 and nucleotide sequence encoding an amino acid sequence of three EGF-like domains. The multimerizing component is immunoglobulin domain.
Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials.
Chronic pain is a prevalent and persistent ailment that affects individuals worldwide. Conventional medications employed in the treatment of chronic pain typically demonstrate limited analgesic effectiveness and frequently give rise to debilitating side effects, such as tolerance and addiction, thereby diminishing patient compliance with medication. Consequently, there is an urgent need for the development of efficacious novel analgesics and innovative methodologies to address chronic pain. Recently, a growing body of evidence has suggested that multireceptor ligands targeting opioid receptors (ORs) are favorable for improving analgesic efficacy, decreasing the risk of adverse effects, and occasionally yielding additional advantages. In this study, the intrathecal injection of a recently developed peptide (VYWEMEDKN) at nanomolar concentrations decreased pain sensitivity in naïve mice and effectively reduced pain-related behaviors in nociceptive pain model mice with minimal opioid-related side effects. Importantly, the compound exerted significant rapid-acting antidepressant effects in both the forced swim test and tail suspension test. It is possible that the rapid antihyperalgesic and antidepressant effects of the peptide are mediated through the OR pathway. Overall, this peptide could both effectively provide pain relief and alleviate depression with fewer side effects, suggesting that it is a potential agent for chronic pain and depression comorbidities from the perspective of pharmaceutical development.
Waitlist control arm. Participants will complete a 4-week control period upon randomization. After this control period is completed, they will crossover into the intervention group and follow the same 4 week intervention as the yoga group.
Selegiline hydrochloride, USP is a levorotatory acetylenic derivative of phenethylamine. It is commonly referred to in the clinical and pharmacological literature as l-deprenyl.

The chemical name is: (R)-(-)-N,2-dimethyl-N-2-propynylphenethylamine hydrochloride. It is a white to near white crystalline powder, freely soluble in water, chloroform, and methanol, and has a molecular weight of 223.75. The molecular formula is C 13H 17N.HCI and the structural formula is as follows: 

Each hard gelatin capsule with white opaque cap and white opaque body imprinted "Novitium 5 mg" on the body and "504" on the cap in red ink containing white to off- white powder. Each capsule contains 5 mg selegiline hydrochloride, USP. Inactive ingredients are citric acid anhydrous, lactose monohydrate, magnesium stearate and microcrystalline cellulose. The capsule shells contain gelatin and titanium dioxide and are imprinted with red ink. The imprinting ink contains shellac, alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, sodium hydroxide, titanium dioxide, povidone and FD&C Red #40, Aluminum Lake.
Peripheral artery disease (PAD) is the lower limb manifestation of systemic atherosclerotic disease. PAD may initially present with symptoms of intermittent claudication, whilst chronic limb-threatening ischaemia (CLTI), the end stage of PAD, presents with rest pain and/or tissue loss. PAD is an age-related condition present in over 10% of those aged ≥65 in high-income countries. Guidelines regarding definition, diagnosis and staging of PAD and CLTI have been updated to reflect the changing patterns and presentations of disease given the increasing prevalence of diabetes. Recent research has changed guidelines on optimal medical therapy, with low-dose anticoagulant plus aspirin recommended in some patients. Recently published randomised trials highlight where bypass-first or endovascular-first approaches may be optimal in infra-inguinal disease. New techniques in endovascular surgery have increased minimally invasive options for ever more complex disease. Increasing recognition has been given to the complexity of patients with CLTI where a high prevalence of both frailty and cognitive impairment are present and a significant burden of multi-morbidity and polypharmacy. Despite advances in minimally invasive revascularisation techniques and reduction in amputation incidence, survival remains poor for many with CLTI. Shared decision-making is essential, and conservative management is often appropriate for older patients. There is emerging evidence of the benefit of specialist geriatric team input in the perioperative management of older patients undergoing surgery for CLTI. Recent UK guidelines now recommend screening for frailty, cognitive impairment and delirium in older vascular surgery patients as well as recommending all vascular surgery services have support and input from specialist geriatrics teams.
G protein-coupled receptors (GPCRs) are ubiquitously expressed cell surface receptors that mediate numerous physiological responses and are highly druggable. Upon activation, GPCRs rapidly couple to heterotrimeric G proteins and are then phosphorylated and internalized from the cell surface. Recent studies indicate that GPCRs not only localize at the plasma membrane but also exist in intracellular compartments where they are competent to signal. Intracellular signaling by GPCRs is best described to occur at endosomes. Several studies have elegantly documented endosomal GPCR-G protein and GPCR-β-arrestin signaling. Besides phosphorylation, GPCRs are also posttranslationally modified with ubiquitin. GPCR ubiquitination has been studied mainly in the context of receptor endosomal-lysosomal trafficking. However, new studies indicate that ubiquitination of endogenous GPCRs expressed in endothelial cells initiates the assembly of an intracellular p38 mitogen-activated kinase signaling complex that promotes inflammatory responses from endosomes. In this mini-review, we discuss emerging discoveries that provide critical insights into the function of ubiquitination in regulating GPCR inflammatory signaling at endosomes.
BACKGROUND: Gastrosplenic fistula is a rare and potentially fatal complication of various conditions. Lymphoma is the most common cause. It can occur spontaneously or after chemotherapy. Gastrosplenic fistula diagnosis can be confused with a splenic abscess because of the presence of air into the mass. The computed tomography identification of the fistulous tract is the key to a right diagnosis. Treatment modalities include surgical resection, chemotherapy, or a combination of both.
CASE PRESENTATION: Here we report two patients with gastrosplenic fistula due to diffuse large B cell lymphoma. The first patient was a 54-year-old Caucasian woman with an enormous primary splenic diffuse large B cell lymphoma leading to the development of a spontaneous fistula in the stomach. The second patient was a 48-year-old Caucasian male patient with an enormous splenic diffuse large B cell lymphoma complicated by fistula after chemotherapy. Both patients died of septic shock several days after surgery.
CONCLUSION: Gastrosplenic fistula is a rare complication with a poor-prognosis, for which surgery is currently the preferred treatment.
Disclosed herein are materials and methods such as the use of none steroidal anti-inflammatory drugs to increase the number of CD34+ cell in human patients. The level of ECFC measured in volunteers before and after treatment with meloxicam. Only 4/7 volunteers had detectable levels of ECFC in a 40 mL sample of peripheral of blood (PB) before treatment, while 7/7 had detectable levels of ECFC in a similar sample collected post-meloxicam treatment. Administering a course of treatment with NSAID also increased the number of endothelial colony forming cells (ECFC) in the volunteers PB and it reduced culture time to first ECFC detection. These data demonstrate that NSAID administration mobilizes both hematopoietic and endothelial progenitors to PB. This provides a safe and effective strategy that can be added to existing mobilization regimens and is especially useful when combined with a course of treatment that includes the use of G-CSF.
PURPOSE: Pharmaceutically allowed salt is produced by using a derivate of pyrido(4,3,-d) pyrimidine-5-on and a protein kinase inhibitor useful for treating cell proliferative disorders such as cancer, autoimmune disease, infection, cardiovascular disease, neurogenerative disease and disability. CONSTITUTION: A protein kinase inhibitor is marked structural formula(I). A pharmaceutical formulation comprises a pharmaceutically allowed carrier, a diluting agent and a compound of structural formula(I). A method of treating protein kinase infected disease comprises a step to inject an effective dose of a compound of structural formula(I) and pharmaceutically allowed salt of the same into the object to be treated. A compound of structural formula(I) is injected one or more than one additional medicine. A compound of structural formula(I) is injected through intravenous injection, subcutaneous injection, suction, oral administration, colorectal administration, non-oral administration, injection into vitneous body, intramuscular medication, nasal administration, skin dose, topical administration, ear administration, ocular medication, oral administration, tracheal administration, bronchus administration or injection in hypoglotis. A method of suppressing of the growth of cancer cells comprises a step to touch cancer cells with a compound of structural formula(I) and pharmaceutically allowed salt. Neurogenerative disease is parkinson's disease or Alzheimer disease.
First surgical eye randomized to CENTURION® Vision System, with second surgical eye (fellow eye) assigned to INFINITI® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
A-tDCS (1 mA) plus Speech and Language Treatment (SALT) for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. The electrical current will be administered to a pre-specified region of the brain. The stimulation will be delivered at an intensity of 1mA for a maximum of 20 minutes. SALT will be a computer-delivered naming + picture matching task .
Specific Aim 1. Investigate sensory, motor, and cognitive-motor mechanisms governing susceptibility to optical flow perturbations. Aging increases the reliance on vision for balance control. However, central and peripheral mechanisms underlying aging and falls history effects on the susceptibility to optical flow perturbations are unclear. Hypothesis 1: Entrainment to optical flow perturbations will correlate most strongly with visual dependence and decreased somatosensory function, alluding to an age-associated process of multi-sensory reweighting. Methods: Multivariate models will quantify the extent to which strategically-selected sensory (i.e., visual dependence via rod/frame test, somatosensory function), motor (i.e., rate of torque development, timed sit-to-stand) and cognitive-motor (i.e., interference) mechanisms underlie inter-individual differences in susceptibility to perturbations.

Specific Aim 2. Estimate the efficacy of prolonged optical flow perturbations to condition the neuromechanics of walking balance control in older adult fallers. Pilot data from young adults suggests that prolonged exposure to optical flow perturbations may condition reactive strategies used to successfully control walking balance. The investigator's premise is that dynamic perturbation training can improve resilience to unexpected balance disturbances. Here, the investigators conduct a preliminary test of the effects of training with optical flow perturbations on walking balance in older adult fallers. Hypothesis 2: (a) Older adults with a history of falls will adapt to prolonged exposure to perturbations, conditioning their step to step adjustments in walking balance control, and (b) improving their response to unexpected balance challenges following training. Methods: In two 20 min sessions, on different days in a randomized cross-over design, older adults with a history of falls will walk with ("treatment" session) and without ("control" session) prolonged exposure to optical flow perturbations. The investigators will assess time-dependent changes in the neuromechanics of walking balance during training and after-effects via gait variability, dynamic stability, and performance on a series of real-world like targeting and obstacle avoidance tasks.
PCT No. PCT/EP97/01581 Sec. 371 Date Sep. 15, 1998 Sec. 102(e) Date Sep. 15, 1998 PCT Filed Mar. 27, 1997 PCT Pub. No. WO97/36972 PCT Pub. Date Oct. 9, 1997A process is disclosed for stabilizing and dispersing vegetable oils which contain polyunsaturated fatty acid radicals by means of  gamma -cyclodextrin, as well as the thus obtained complexes and their use. In this process for stabilizing vegetable oils having a high proportion of triacylglycerines and containing polyunsaturated fatty acids, cyclodextrin is mixed with vegetable oil and so a cyclodextrin/vegetable oil complex is formed. This process is characterized in that  gamma -cyclodextrin is used to form complexes with vegetable oils.
Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur. Serious intracerebral hemorrhages > 1 cm, some of which have been fatal, have been observed in patients treated with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy to a patient being treated with LEQEMBI [see Warnings and Precautions (5.1), Adverse Reactions (6.1)]. 

ApoE ε4 Homozygotes 

Patients who are apolipoprotein E ε4 (ApoE ε4) homozygotes (approximately 15% of Alzheimer’s disease patients) treated with this class of medications, including LEQEMBI, have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed they can still be treated with LEQEMBI; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA [see Warnings and Precautions (5.1)]. 

Consider the benefit of LEQEMBI for the treatment of Alzheimer’s disease and potential risk of serious adverse events associated with ARIA when deciding to initiate treatment with LEQEMBI [see Warnings and Precautions (5.1) and Clinical Studies (14)].
The transition from acute kidney injury (AKI) to chronic kidney disease (CKD) is a critical clinical issue. Although previous studies have suggested macrophages as a key player in promoting inflammation and fibrosis during this transition, the heterogeneity and dynamic characterization of macrophages are still poorly understood. Here, we used integrated single-cell RNA sequencing and spatial transcriptomic to characterize the spatiotemporal heterogeneity of macrophages in murine AKI-to-CKD model of unilateral ischemia-reperfusion injury. A marked increase in macrophage infiltration at day 1 was followed by a second peak at day 14 post AKI. Spatiotemporal profiling revealed that injured tubules and macrophages co-localized early after AKI, whereas in late chronic stages had spatial proximity to fibroblasts. Further pseudotime analysis revealed two distinct lineages of macrophages in this transition: renal resident macrophages differentiated into the pro-repair subsets, whereas infiltrating monocyte-derived macrophages contributed to chronic inflammation and fibrosis. A novel macrophage subset, extracellular matrix remodeling-associated macrophages (EAMs) originating from monocytes, linked to renal fibrogenesis and communicated with fibroblasts via insulin-like growth factors (IGF) signalling. In sum, our study identified the spatiotemporal dynamics of macrophage heterogeneity with a unique subset of EAMs in AKI-to-CKD transition, which could be a potential therapeutic target for preventing CKD development.
One fourth of patients with peripheral artery disease (PAD) of the lower extremities have severe symptomatic disease and 1-2% have critical limb ischemia (CLI). In patients with CLI, the risk of limb amputation at 1 year is 50%. In addition, patients with CLI often have rest pain, non-healing ulcers and severe limitations of ambulation. Revascularization procedures, including bypass surgery, percutaneous transluminal angioplasty and angioplasty with stenting, are currently the only treatment options. However, many patients are not eligible for a revascularization procedure due to small vessel disease or coexisting medical problems. Moreover, restenosis rates are high.

There is currently no effective non-invasive treatment for critical limb ischemia. We hypothesize that mobilization of angiogenic cells into the blood by granulocyte colony stimulating factor (G-CSF) may stimulate angiogenesis in areas of ischemia and result in a sustained improvement in blood flow in patients with severe PAD.
Table 3 lists treatment-emergent adverse events that occurred in ≥2% of patients with advanced Parkinson’s disease (with L-dopa) treated with ropinirole hydrochloride who participated in the double-blind, placebo-controlled studies and were numerically more common in the group treated with ropinirole hydrochloride. In these studies, either ropinirole hydrochloride or placebo was used as an adjunct to L-dopa. Adverse events were usually mild or moderate in intensity. 

The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical studies. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. However, the cited figures do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the adverse events incidence rate in the population studied.

Other events reported by 1% or more of patients treated with both ropinirole hydrochloride and L-dopa, but equally or more frequent in the placebo/L-dopa group, were: myocardial infarction, orthostatic symptoms, virus infections, asthenia, dyspepsia, myalgia, back pain, depression, leg cramps, fatigue, rhinitis, chest pain, hematuria, vertigo, tinnitus, leg edema, hot flushes, abnormal gait, hyperkinesia, and pharyngitis.

Among the treatment-emergent adverse events in patients treated with ropinirole hydrochloride, hallucinations and dyskinesias appear to be dose-related.